# Cara Therapeutics Inc. (TVRD)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $7M  
**Price:** $2.70 (-2.88%)

> Cara Therapeutics Inc. is a biopharmaceutical company developing innovative treatments targeting the peripheral nervous system and immune cells. The company's lead product, KORSUVA, represents a significant advancement in addressing chronic itch and other conditions affecting patients with limited treatment options. Cara Therapeutics focuses on identifying and developing novel therapeutics to address unmet medical needs in dermatology and other therapeutic areas. By leveraging its expertise in peripheral nervous system biology, the company aims to bring transformative medicines to market that improve patient outcomes and quality of life. The organization operates within the broader biotechnology sector, contributing to the development of next-generation therapies for conditions that significantly impact patient populations worldwide.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2024 | $7M | — | -$28M | -$29M | — |
| 2023 | $21M | — | -$121M | -$119M | — |
| 2022 | $42M | — | -$88M | -$85M | — |
| 2021 | $23M | — | -$89M | -$88M | — |
| 2020 | $135M | — | $5M | $8M | — |
| 2019 | $20M | — | -$112M | -$106M | — |
| 2018 | $13M | — | -$77M | -$74M | — |
| 2017 | $911,000 | — | -$59M | -$58M | — |
| 2016 | $86,000 | — | -$58M | -$57M | — |
| 2015 | $4M | — | -$25M | -$25M | — |
| 2014 | $3M | — | -$18M | -$18M | — |
| 2013 | $12M | — | -$237,000 | -$4M | — |
| 2012 | $1M | — | -$6M | -$6M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2024 | $35M | $41M | -$91M | $32M | — |
| 2023 | $126M | $69M | -$62M | $52M | — |
| 2022 | $182M | $23M | $159M | $64M | — |
| 2021 | $247M | — | $228M | $13M | — |
| 2020 | $271M | — | $249M | $32M | — |
| 2019 | $233M | — | $187M | $18M | — |
| 2018 | $191M | — | $134M | $15M | — |
| 2017 | $97M | — | $87M | $9M | — |
| 2016 | $64M | — | $51M | $12M | — |
| 2015 | $111M | — | $105M | $15M | — |
| 2014 | $56M | — | $52M | $53M | — |
| 2013 | $18M | — | -$54M | $12M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$23M | — | — |
| 2024 | -$18M | $1M | -$19M |
| 2023 | -$92M | $2M | -$94M |
| 2022 | -$79M | $43,000 | -$79M |
| 2021 | -$60M | $39,000 | -$60M |
| 2020 | -$5M | $349,000 | -$6M |
| 2019 | -$109M | $18,000 | -$109M |
| 2018 | -$22M | $73,000 | -$22M |
| 2017 | -$55M | $58,000 | -$55M |
| 2016 | -$47M | $717,000 | -$48M |

Source: [CompaniesByCap](https://companiesbycap.com/company/TVRD)